Compare ADMA Biologics Inc (ADMA) vs Huntington Ingalls Industries Inc (HII) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

HII trades at $294.10, up 0.89% with a bullish technical signal supported by recent contract wins and strong earnings beats. The company maintains solid fundamentals with a 4.71% net margin and 12.2% ROE, while analyst consensus targets $384.50 representing 31% upside potential. Recent developments include a $418 million Navy contract and expansion in unmanned systems production.

HII presents a compelling investment case with consistent earnings outperformance, robust defense contracts, and attractive valuation metrics. Key risks include defense budget dependencies and execution challenges, but the company's $54 billion backlog and strategic positioning in naval shipbuilding support long-term growth prospects.